Mereo BioPharma Group plc (Mereo) (MREO): Price and Financial Metrics
GET POWR RATINGS... FREE!
MREO POWR Grades
- MREO scores best on the Value dimension, with a Value rank ahead of 77.34% of US stocks.
- The strongest trend for MREO is in Growth, which has been heading up over the past 179 days.
- MREO's current lowest rank is in the Quality metric (where it is better than 6.04% of US stocks).
MREO Stock Summary
- With a year-over-year growth in debt of -46.26%, MEREO BIOPHARMA GROUP PLC's debt growth rate surpasses merely 6.86% of about US stocks.
- In terms of twelve month growth in earnings before interest and taxes, MEREO BIOPHARMA GROUP PLC is reporting a growth rate of -150.46%; that's higher than just 10.62% of US stocks.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for MREO comes in at -55.32% -- higher than that of just 10.44% of stocks in our set.
- Stocks that are quantitatively similar to MREO, based on their financial statements, market capitalization, and price volatility, are LOGC, LCTX, MRNS, RKLY, and IMV.
- Visit MREO's SEC page to see the company's official filings. To visit the company's web site, go to www.mereobiopharma.com.
MREO Stock Price Chart Interactive Chart >
MREO Price/Volume Stats
| Current price | $1.00 | 52-week high | $1.85 |
| Prev. close | $0.99 | 52-week low | $0.30 |
| Day low | $0.98 | Volume | 278,200 |
| Day high | $1.02 | Avg. volume | 839,778 |
| 50-day MA | $0.78 | Dividend yield | N/A |
| 200-day MA | $0.94 | Market Cap | 124.99M |
Mereo BioPharma Group plc (Mereo) (MREO) Company Bio
Mereo BioPharma Group plc (Mereo) operates as a clinical stage biopharmaceutical company. The Company develops medicines for rare and specialty diseases. Mereo serves the healthcare sector globally.
Latest MREO News From Around the Web
Below are the latest news stories about MEREO BIOPHARMA GROUP PLC that investors may wish to consider to help them evaluate MREO as an investment opportunity.
Positive week for Mereo BioPharma Group plc (NASDAQ:MREO) hedge funds investors who lost 33% over the past yearA look at the shareholders of Mereo BioPharma Group plc ( NASDAQ:MREO ) can tell us which group is most powerful. We... |
Have you been able to find a good deal on Mereo BioPharma Group plc’s shares?In Friday’s session, Mereo BioPharma Group plc (NASDAQ:MREO) marked $0.50 per share, down from $0.56 in the previous session. While Mereo BioPharma Group plc has underperformed by -10.61%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MREO fell by -69.10%, with highs and lows ranging from […] |
MEREO BIOPHARMA (MREO) Loses 25.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerThe heavy selling pressure might have exhausted for MEREO BIOPHARMA (MREO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare ConferenceLONDON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 12:55pm |
Mereo BioPharma receives Nasdaq notice for non-complianceMereo BioPharma (MREO) has received a notification letter from Nasdaq as it failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days.In the event… |
MREO Price Returns
| 1-mo | 91.75% |
| 3-mo | 1.01% |
| 6-mo | -17.36% |
| 1-year | -7.41% |
| 3-year | -43.50% |
| 5-year | N/A |
| YTD | 33.33% |
| 2022 | -53.13% |
| 2021 | -55.31% |
| 2020 | 9.15% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...